Advertisement

Il trattamento del diabete di tipo 1: dalle nuove insuline ai farmaci orali

  • Anna Rita MauriziEmail author
  • Silvia Pieralice
  • Paolo Pozzilli
Rassegna
  • 8 Downloads

Sommario

Ancora oggi il trattamento insulinico rappresenta il cardine nella gestione dei pazienti affetti da diabete mellito tipo 1 (DMT1). Al fine di garantire una maggior flessibilità nella gestione della terapia, sono state recentemente immesse in commercio nuove insuline basali, ad azione più prolungata e stabile, e nuove insuline prandiali a minor latenza d’azione, che mostrano una farmacocinetica in grado di ricalcare più da vicino la fisiologica produzione pancreatica di insulina. Analogamente, l’aggiunta di trattamenti ipoglicemizzanti tipicamente utilizzati nel diabete mellito tipo 2 (DMT2) ha mostrato risultati incoraggianti sia in termini di miglioramento del compenso glicemico che di sicurezza terapeutica nei pazienti con DMT1. Per tale motivo, sulla base delle evidenze scientifiche emerse dai diversi trial clinici è sempre più diffuso l’utilizzo nella pratica clinica di farmaci come la metformina, gli inibitori del co-trasportatore di sodio glucosio 2 (SGLT2), gli agonisti del recettore del peptide 1 glucagone-simile (GLP-1) e gli inibitori della dipeptidil peptidasi-4 (DPP-4). Ciò nonostante, sono necessari ulteriori studi multicentrici e randomizzati al fine di confermarne l’efficacia e la sicurezza a lungo termine.

Parole chiave

Diabete tipo 1 Terapia insulinica Metformina Inibitori del co-trasportatore di sodio glucosio 2 (SGLT2) Agonisti del recettore del peptide GLP-1 Inibitori della dipeptidil peptidasi-4 

Notes

Conflitto di interesse

Gli autori Anna Rita Maurizi, Silvia Pieralice e Paolo Pozzilli dichiarano di non avere conflitti di interesse.

Consenso informato

Lo studio presentato in questo articolo non ha richiesto sperimentazione umana.

Studi sugli animali

Gli autori di questo articolo non hanno eseguito studi sugli animali.

Supplementary material

40619_2019_514_MOESM1_ESM.doc (31 kb)
Scheda di autovalutazione (DOC 31 kB)
40619_2019_514_MOESM2_ESM.doc (28 kb)
RISPOSTE (DOC 28 kB)

Bibliografia

  1. 1.
    American Diabetes Association (2018) Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018. Diabetes Care 41(Suppl 1):S73–S85 CrossRefGoogle Scholar
  2. 2.
    Thalange N, Deeb L, Iotova V et al. (2015) Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes. Pediatr Diabetes 16:164–176 CrossRefGoogle Scholar
  3. 3.
    Mathieu C, Hollander P, Miranda-Palma B et al. (2013) Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab 98(3):1154–1162 CrossRefGoogle Scholar
  4. 4.
    Heller S, Buse J, Fisher M et al. (2012) Insulin degludec, an ultra-long acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target noninferiority trial. Lancet 379(9825):1489–1497 CrossRefGoogle Scholar
  5. 5.
    Becker RH, Dahmen R, Bergmann K et al. (2015) New insulin glargine 300 Units mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units mL-1. Diabetes Care 38:637–643 Google Scholar
  6. 6.
    Home PD, Bergenstal RM, Riddle MC et al. (2015) New insulin glargine 300 Units/mL versus glargine 100 Units/mL in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4). Diabetes Care 38(12):2217–2225 CrossRefGoogle Scholar
  7. 7.
    Heise T, Pieber TR, Danne T et al. (2017) A pooled analysis of clinical pharmacology trials investigating the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in adults with type 1 diabetes. Clin Pharmacokinet 56:551–559 CrossRefGoogle Scholar
  8. 8.
    Bode BW, Garg SK (2016) The emerging role of adjunctive noninsulin antihyperglycemic therapy in the management of type 1 diabetes. Endocr Pract 22(2):220–230 CrossRefGoogle Scholar
  9. 9.
    Frandsen CS, Dejgaard TF, Madsbad S (2016) Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus. Lancet Diabetes Endocrinol 4(9):766–780 CrossRefGoogle Scholar
  10. 10.
    Abdelghaffar S, Attia AM (2009) Metformin added to insulin therapy for type 1 diabetes mellitus in adolescents. Cochrane Database Syst Rev 1:CD006691 Google Scholar
  11. 11.
    Libman IM, Miller KM, DiMeglio LA (2015) T1D Exchange Clinic Network Metformin RCT Study Group. Effect of metformin added to insulin on glycemic control among overweight/obese adolescents with type 1 diabetes: a randomized clinical trial. JAMA 314:2241–2250 CrossRefGoogle Scholar
  12. 12.
    Zinman B, Wanner C, Lachin JM et al. (for the EMPA-REG OUTCOME Investigators) (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128 CrossRefGoogle Scholar
  13. 13.
    Garg SK, Henry RR, Banks P et al. (2017) Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med 377(24):2337–2348 CrossRefGoogle Scholar
  14. 14.
    Biester T, Aschemeier B, Fath M et al. (2017) Effects of dapagliflozin on insulin-requirement, glucose excretion and ß-hydroxybutyrate levels are not related to baseline HbA1c in youth with type 1 diabetes. Diabetes Obes Metab 19(11):1635–1639 CrossRefGoogle Scholar
  15. 15.
    US Food and Drug Administration. FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. http://www.fda.gov/Drugs/DrugSafety/ucm475463.htm. Published January 7, 2016. Accessed June 10, 2016
  16. 16.
    Dejgaard TF, Frandsen CS, Hansen TS et al. (2016) Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 4(3):221–232 CrossRefGoogle Scholar
  17. 17.
    Buzzetti PP, Frederich R et al. (2016) Saxagliptin improves glycaemic control and C-peptide secretion in latent autoimmune diabetes in adults (LADA). Diabetes Metab Res Rev 32(3):289–296 CrossRefGoogle Scholar
  18. 18.
    Giampietro O, Giampietro C, Bartola LD et al. (2013) Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes. Drug Des Devel Ther 7:99–104 Google Scholar
  19. 19.
    Underland LJ, Ilkowitz JT, Katikaneni R et al. (2017) Use of sitagliptin with closed-loop technology to decrease postprandial blood glucose in type 1 diabetes. J Diabetes Sci Technol 11(3):602–610 CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Anna Rita Maurizi
    • 1
    Email author
  • Silvia Pieralice
    • 1
  • Paolo Pozzilli
    • 1
  1. 1.Unità di Endocrinologia e Diabetologia, Dipartimento di MedicinaUniversità Campus Bio-Medico di RomaRomaItalia

Personalised recommendations